
    
      Randomized Phase II Clinical Study of Radiation Therapy, Hormone Therapy and Chemotherapy
      with Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients with High-Risk
      Localized Prostate Cancer (Stage III and IV) Primary Objective: To determine the percentage
      of patients free of biochemical recurrence within 5 years of receiving a combination of
      radiation therapy with docetaxel associated with hormone therapy or the standard of care of
      radiation therapy and hormone therapy in patients with stage III and IV localized prostate
      cancer with a poor prognosis.

      Design: A prospective, multicenter, multidisciplinary, parallel-group, open-label study with
      randomized group assignment.
    
  